Different growth hormone sensitivity of target tissues and growth hormone response to glucose in HIV-infected patients with and without lipodystrophy
- PMID: 15764170
- DOI: 10.1080/00365540410021162
Different growth hormone sensitivity of target tissues and growth hormone response to glucose in HIV-infected patients with and without lipodystrophy
Abstract
Growth hormone (GH)-secretion in HIV-lipodystrophy is impaired; however, GH-sensitivity of GH-target tissues remains to be evaluated. We measured overnight fasting concentrations of GH-sensitive insulin-like growth-factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) including GH binding protein (GHBP), a marker of GH-receptor sensitivity, in antiretroviral treated HIV-infected patients with (LIPO) and without lipodystrophy (NONLIPO) and antiretroviral naive HIV-infected patients (NAIVE). Three h GH-suppression tests using oral glucose were undertaken to determine dynamics of GH-secretion. IGF-I and IGFBP-3 were increased in LIPO compared with NONLIPO (p <0.05), but did not differ significantly between NONLIPO and NAIVE. Area under the curve of GH (AUC-GH) during the GH-suppression test was decreased in LIPO compared with NONLIPO (p <0.05). Ratio of limb to trunk fat, which was decreased in LIPO compared to NONLIPO and NAIVE (p <0.001), correlated positively with AUC-GH and rebound-GH (p <0.05). All groups displayed suppression of GH during the suppression test (p <0.05) and all groups, except LIPO, displayed a rebound of GH (p <0.05), which probably is explained by persistently increased plasma glucose in LIPO compared with NONLIPO and NAIVE (p <0.01). GHBP was inversely correlated with AUC-GH (p <0.01). Our data suggest that GH-target tissues in LIPO are at least as GH-sensitive as in HIV-infected patients without lipodystrophy.
Similar articles
-
Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy.J Clin Endocrinol Metab. 2001 Feb;86(2):504-10. doi: 10.1210/jcem.86.2.7175. J Clin Endocrinol Metab. 2001. PMID: 11158000
-
Insulin-like growth factors, insulin-like growth factor-binding proteins, insulin-like growth factor-binding protein-3 protease, and growth hormone-binding protein in lipodystrophic human immunodeficiency virus-infected patients.Metabolism. 2004 Dec;53(12):1565-73. doi: 10.1016/j.metabol.2004.06.025. Metabolism. 2004. PMID: 15562401
-
Impaired proinsulin secretion before and during oral glucose stimulation in HIV-infected patients who display fat redistribution.Metabolism. 2007 Jul;56(7):939-46. doi: 10.1016/j.metabol.2007.02.007. Metabolism. 2007. PMID: 17570256
-
Growth hormone deficiency and human immunodeficiency virus.Best Pract Res Clin Endocrinol Metab. 2017 Feb;31(1):91-111. doi: 10.1016/j.beem.2017.02.006. Epub 2017 Feb 24. Best Pract Res Clin Endocrinol Metab. 2017. PMID: 28477736 Review.
-
Recombinant human growth hormone: rationale for use in the treatment of HIV-associated lipodystrophy.BioDrugs. 2008;22(2):101-12. doi: 10.2165/00063030-200822020-00003. BioDrugs. 2008. PMID: 18345707 Review.
Cited by
-
Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS.Rev Endocr Metab Disord. 2013 Jun;14(2):113-8. doi: 10.1007/s11154-013-9245-9. Rev Endocr Metab Disord. 2013. PMID: 23657561 Review.
-
Distinct metabolic surrogates predict basal and rebound GH secretion after glucose ingestion in men.J Clin Endocrinol Metab. 2012 Jun;97(6):2172-9. doi: 10.1210/jc.2011-3317. Epub 2012 Apr 3. J Clin Endocrinol Metab. 2012. PMID: 22472562 Free PMC article. Clinical Trial.
-
GH/GHRH axis in HIV lipodystrophy.Pituitary. 2009;12(2):143-52. doi: 10.1007/s11102-008-0092-8. Pituitary. 2009. PMID: 18270841
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous